Quadcap Wealth Management LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Quadcap Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 631 shares of the biopharmaceutical company’s stock, valued at approximately $478,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. LCM Capital Management Inc lifted its position in shares of Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares during the period. Arjuna Capital increased its stake in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares in the last quarter. Oakworth Capital Inc. increased its stake in Regeneron Pharmaceuticals by 25.0% in the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 14 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Regeneron Pharmaceuticals by 1.8% in the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 15 shares in the last quarter. Finally, Glenview Trust Co raised its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the third quarter. Glenview Trust Co now owns 4,421 shares of the biopharmaceutical company’s stock valued at $3,352,000 after purchasing an additional 17 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.2%

Shares of Regeneron Pharmaceuticals stock traded up $1.45 during trading hours on Friday, reaching $904.35. The company’s stock had a trading volume of 1,122,229 shares, compared to its average volume of 793,479. The company has a market capitalization of $93.11 billion, a P/E ratio of 19.97, a P/E/G ratio of 1.51 and a beta of 0.10. The stock’s fifty day simple moving average is $804.38 and its two-hundred day simple moving average is $742.81. Regeneron Pharmaceuticals, Inc. has a one year low of $591.52 and a one year high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the previous year, the firm posted $11.83 earnings per share. The firm’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Bank of America upped their price target on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. Evercore increased their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Piper Sandler increased their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Finally, Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a “sector perform” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $898.97.

Insider Activity

In other news, EVP Joseph Larosa sold 4,466 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the sale, the executive vice president directly owned 38,906 shares of the company’s stock, valued at $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine Poon sold 7,830 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the transaction, the director owned 5,219 shares in the company, valued at $5,057,680.71. This represents a 60.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 28,228 shares of company stock worth $25,985,950. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.